Matching trials
384 results
- CALLAIndependent statistical analysis of the CALLA phase 3 trial of durvalumab with chemoradiotherapy in women with locally advanced cervical cancer, including trial design, progression-free survival, overall survival, response endpoints, safety, and statistical…
- CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…
- CANTATAComplete statistical analysis of the phase 3 CANTATA trial, including trial design, HbA1c efficacy, secondary metabolic endpoints, ANCOVA, logistic regression, confidence intervals, and statistical interpretation.
- CAPItello-291Independent statistical analysis of CAPItello-291, a randomized phase 3 trial of capivasertib plus fulvestrant versus placebo plus fulvestrant in locally advanced or metastatic HR+/HER2- breast cancer, including progression-free survival and the trial's…
- CAPRISA 008Independent statistical analysis of CAPRISA 008, a randomized phase 2/3 trial evaluating 1% tenofovir gel provision through family planning services for HIV prevention, including adherence, HIV incidence, pregnancy, HPV, and safety analyses.
- CARE-MS IIndependent statistical analysis of CARE-MS I, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including endpoint definitions, hazard ratios, rate ratios, longitudinal analyses, and statistical interpretation.
- CARE-MS IIComplete statistical analysis of CARE-MS II, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including primary endpoints, statistical methods, secondary analyses, safety, and interpretation.
- CAROLINAIndependent statistical analysis of the CAROLINA phase 3 trial comparing linagliptin with glimepiride in patients with type 2 diabetes, including non-inferiority testing, cardiovascular outcomes, glycaemic control, ANCOVA, Cox regression, and logistic regression.
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CATNONIndependent statistical analysis of CATNON (NCT00626990), a randomized phase 3 trial evaluating concomitant and adjuvant temozolomide in anaplastic glioma without 1p/19q loss of heterozygosity.
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-037Independent statistical analysis of CheckMate-037, a randomized phase 3 trial of BMS-936558 (nivolumab) versus Investigator's Choice in unresectable or metastatic melanoma.
- CheckMate-057Independent statistical analysis of CheckMate-057, a randomized phase 3 trial comparing nivolumab with docetaxel in previously treated metastatic non-squamous non-small cell lung cancer, including overall survival, hazard ratio, log-rank testing, and interpretation.
- CheckMate-078Independent statistical analysis of CheckMate-078, a randomized phase 3 trial comparing nivolumab with docetaxel in previously treated advanced or metastatic non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-227Independent statistical analysis of CheckMate-227 (NCT02477826), including randomized trial design, time-to-event endpoints, hazard ratios, confidence intervals, statistical methodology, safety, and interpretation.
- CheckMate-238Independent statistical analysis of CheckMate-238, a randomized phase 3 trial of nivolumab versus ipilimumab for prevention of melanoma recurrence after complete resection of stage IIIb/c or stage IV melanoma.
- CheckMate-274Independent statistical analysis of CheckMate-274 (NCT02632409), a randomized phase 3 trial of nivolumab versus placebo following surgery for bladder or upper urinary tract cancer, including its disease-free survival endpoints, Cox model results,…
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CheckMate-649Independent statistical analysis of CheckMate-649, a randomized phase 3 trial of nivolumab plus chemotherapy versus chemotherapy in stomach cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, focusing on overall survival, progression-free survival, hazard…
- CheckMate-651Independent statistical analysis of CheckMate-651, a randomized phase 3 trial of nivolumab plus ipilimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and…
- CheckMate-76KComplete statistical analysis of CheckMate-76K, the randomized phase 3 trial of nivolumab versus placebo for prevention of recurrent melanoma after complete resection of stage IIB/C melanoma.
- CheckMate-816Independent statistical analysis of CheckMate-816, a randomized phase 3 trial of nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone in early-stage non-small cell lung cancer.
- CheckMate-914Independent statistical analysis of CheckMate-914, a randomized phase 3 trial of nivolumab, nivolumab plus ipilimumab, and placebo in participants with localized renal cell carcinoma after surgery.
- CheckMate-9ERIndependent statistical analysis of CheckMate-9ER, the phase 3 randomized trial of nivolumab combined with cabozantinib versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
- CIRTComplete statistical analysis of CIRT (NCT01594333), a randomized phase 3 trial of methotrexate versus placebo in cardiovascular disease, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, stratification, multiplicity, safety, and statistical…
- CLARITYIndependent statistical analysis of the phase 3 CLARITY trial of oral cladribine in relapsing-remitting multiple sclerosis, including randomized design, annualized qualifying relapse rate, relative risks, confidence intervals, chi-squared testing, intention-to-treat analysis, and…
- CLEARIndependent statistical analysis of the phase 3 CLEAR trial of lenvatinib plus everolimus or lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma, focusing on progression-free survival and the trial's time-to-event…
- CLEAR OutcomesIndependent statistical analysis of CLEAR Outcomes, the randomized phase 3 trial of bempedoic acid versus placebo in statin-intolerant participants with or at high risk for cardiovascular disease, including MACE, secondary time-to-event endpoints,…
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- CLL14Independent statistical analysis of the CLL14 phase 3 trial comparing obinutuzumab plus venetoclax with obinutuzumab plus chlorambucil in chronic lymphocytic leukemia, including time-to-event and response analyses.
- CLOVERSIndependent statistical analysis of the CLOVERS phase 3 trial comparing restrictive fluids with liberal fluids in patients with septic shock, including trial design, primary mortality analysis, secondary outcomes, statistical methodology, and interpretation.
- CodeBreaK 200Independent statistical analysis of CodeBreaK 200, a randomized phase 3 trial comparing AMG 510 (sotorasib) with docetaxel in KRAS G12C-mutated advanced or metastatic NSCLC, including progression-free survival, hazard ratios, confidence intervals, log-rank…
- COMBI-ADAn independent statistical analysis of the phase 3 COMBI-AD trial of dabrafenib with trametinib in high-risk BRAF V600 mutation-positive melanoma, including trial design, relapse-free survival, secondary time-to-event analyses, statistical methods, and interpretation.
- COMBI-vIndependent statistical analysis of the COMBI-v phase 3 trial of dabrafenib plus trametinib versus vemurafenib in unresectable or metastatic BRAF V600E/K cutaneous melanoma, including trial design, time-to-event endpoints, hazard ratios, confidence intervals,…
- COMET-1Independent statistical analysis of COMET-1, the randomized phase 3 trial of cabozantinib versus prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or MDV3100.
- COMPARZIndependent statistical analysis of the COMPARZ phase 3 trial comparing pazopanib with sunitinib in locally advanced and/or metastatic renal cell carcinoma, including its progression-free survival endpoint, non-inferiority framework, Cox model, and reported…
- COMPASSIndependent statistical analysis of the COMPASS phase 3 trial of rivaroxaban-based antithrombotic treatment in coronary or peripheral artery disease, including trial design, time-to-event endpoints, hazard ratios, safety outcomes, statistical methods, and interpretation.
- CONTACT-01Independent statistical analysis of CONTACT-01, a randomized phase 3 trial of atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- COSMIC-312Complete statistical analysis of COSMIC-312, the randomized phase 3 trial of cabozantinib plus atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma, including its time-to-event endpoints, hazard ratios, confidence intervals, p-values, and…
- COSMIC-313Independent statistical analysis of COSMIC-313, a randomized phase 3 trial of cabozantinib with nivolumab and ipilimumab versus placebo with nivolumab and ipilimumab in previously untreated advanced or metastatic renal cell carcinoma.
- COSSIndependent statistical analysis of the COSS phase 3 trial of extracranial-intracranial bypass surgery versus best medical therapy for symptomatic carotid occlusion, including its primary endpoint, secondary analyses, statistical methods, and interpretation.
- COU-AA-301Independent statistical analysis of COU-AA-301, a randomized phase 3 trial of abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, covering overall survival, progression, PSA response, trial design, and statistical…
- COVACTAIndependent statistical analysis of the randomized phase 3 COVACTA trial evaluating tocilizumab versus placebo in patients with severe COVID-19 pneumonia, including endpoint definitions, reported treatment effects, confidence intervals, p-values, and statistical methodology.
- CREDENCEComplete statistical analysis of CREDENCE, the randomized phase 3 trial evaluating canagliflozin versus placebo for renal and cardiovascular outcomes in participants with type 2 diabetes and diabetic nephropathy.
- CRYSTALIndependent statistical analysis of the CRYSTAL phase 3 trial of cetuximab plus FOLFIRI versus FOLFIRI alone in EGFR-expressing metastatic colorectal cancer, including progression-free survival, overall survival, response, statistical methods, and interpretation.
- D-CAREIndependent statistical analysis of the D-CARE phase 3 trial of denosumab as adjuvant treatment for women with high-risk early breast cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, stratified log-rank…